The Tale of a "Breakthrough" That Isn't New
When headlines scream "major breakthrough" for a hair loss treatment, it's natural to feel a spark of hope. But as someone who's spent years studying the science behind these claims, I've learned that the loudest buzz often comes from the least groundbreaking places. This is the story of TH07—a treatment that's making waves in the media right now, but whose roots go much deeper than the recent hype suggests.
You see, the study that's fueling this excitement was published about two years ago, yet here we are in 2024, and it's being presented as a fresh discovery. The real story begins with a simple combination: TH07 is a topical solution that blends three already-familiar ingredients—5% minoxidil, 0.1% finasteride, and 0.003% latanoprost. No novel ingredient here, just a mix of proven tools. But the way it's being marketed—with phrases like "triple mechanism" and "synergistic effect"—makes it sound like a revolution. Let me walk you through what the data actually says, and whether this is something you should really care about.
The Study Beneath the Surface
The trial was a randomized, double-blind design, comparing the combo (TH07) against each ingredient alone, with four groups in total. The duration was six months, with once-daily topical application. Participants were men aged 19 to 65, with mild to moderate androgenetic alopecia (Norwood 2 through 5). Results were measured through standardized scalp photography, investigator grading, and patient self-assessment.
On the surface, the numbers look impressive. In the TH07 group, 52% achieved dense regrowth, 30% moderate, and 17% minimal regrowth. In contrast, the monotherapy groups saw up to 77% with no regrowth. Patient satisfaction was higher with TH07. Statistically, the combo outperformed individual treatments. If you stop there, it seems like a breakthrough.
The Cracks in the Foundation
But as I always say, the devil is in the details. Look closer at the patient numbers: the TH07 group had 23 patients, while the other groups had only three to four each. That's a stark imbalance. When you have such small groups, the statistical power drops dramatically. Conclusions become shaky, and comparisons become unreliable. This isn't a balanced test—it's a flawed one.
Another critical issue: all treatments were topical applications. They never compared TH07 to oral finasteride or oral minoxidil—the gold standard first-line treatments. Oral finasteride prevents further hair loss, while oral minoxidil encourages fullness. These are the proven, potent options that millions use. But the study ignored them entirely, leaving a huge gap in evidence.
Subjective Measures and Missing Data
The results were also highly subjective. They didn't measure hair density or caliber using objective tools like trichoscopy. Instead, investigators graded photos with categories like "no growth," "minimal growth," "moderate growth," or "dense regrowth." Patients gave their own impressions on appearance, satisfaction, and perceived slowing of loss. This is all opinion-based—not the hard data we need to trust a treatment.
As for safety, the short-term profile looked acceptable. No systemic side effects or sexual side effects were reported, just a few cases of scalp irritation. But that irritation might come from the vehicle (propylene glycol) or from latanoprost itself, which is known to cause irritation. Long-term scalp data? None. That's a red flag.
The Latanoprost Wild Card
The perceived novelty of TH07 is the inclusion of latanoprost, a prostaglandin analog used for glaucoma. It was discovered to increase eyelash growth as a side effect, sparking interest in scalp hair regrowth. The best study we have on this is from 2012—more than a decade ago—with just 16 patients and mild hair loss. It showed some increase in density, but it's never been reproduced in a male androgenetic alopecia study. Compare that to minoxidil and finasteride, backed by decades of robust research. Latanoprost remains a small, early-stage idea with unknown long-term effects when applied broadly to large scalp areas—like irritation, pigmentation changes, or unwanted hair growth in unintended places.
The Bottom Line: What This Really Means
So, what does this study tell us? Combining multiple known-effective treatments can potentially amplify results—a principle we already apply in clinical practice. We attack hair loss from different angles: prevent further loss and improve quality. But TH07 is not working under a new mechanism or a new class of drugs. It's a convenience play, combining things we already know. That's not innovation.
The company behind TH07 is recruiting for a phase 3 trial in Canada and India, but I think this is far less exciting than emerging approaches like monounsaturated fatty acids, PP405, or Classerone—each targeting new biology. Meanwhile, I question whether 0.1% topical finasteride is strong enough to prevent hair loss in most men. Standard dosages are 0.25% to 0.3%, so 0.1% is quite weak.
In the end, could this combo help? Maybe. But the evidence is limited, from a small, short-term, unbalanced study. We don't know how it compares to oral medications—the real gold standard. When excitement flares around something new, remember the tried-and-true: anything that can help can also hurt. That's the hard reality of medicine. So before getting swept up in the headlines, look beyond the buzz. True progress comes from thorough science, not recycled media stories.